Asian Market Expansion for New Infectious Disease Treatment
29 October 2019Read Case Study
Black Swan Analysis founded
Opened first office
Rx Pricing launch
200 Epiomic diseases
Black Swan Analysis is a unique analysis practice that provides robust valuations and commercialisation plans to optimise products in the healthcare industry. We know what it takes to succeed in this industry and we are committed to bringing insight and high-quality solutions to our clients.
The combination of a talented professional team and a comprehensive set of proprietary databases (Epiomic ™, Oncostrat ™, RxPriceIndex ™ & TheJourney ™) allow for our clients to make well-informed decisions in rapidly evolving pharmaceutical landscapes. Our philosophy at Black Swan is to create the right environment using inclusive dialogues and collaboration that enable us to generate outputs that make business decisions clear.
The Black Swan team has a unique skill set: the ability to develop dynamic market forecasts and interactive patient flow models using a wide range of data including complex pathological and epidemiological information. As pharmaceutical and healthcare companies are challenged to deliver more specific targets that align with unmet medical needs. These modelling approaches are more commercially focused to meet the requirements of a changing healthcare environment.
We have the capability to provide an immediate and ‘hands-on’ approach with every client and where the right internal expertise is leveraged we can help find your optimal solution. Using our bespoke methodologies and frameworks we seek to assess the most challenging valuations.
The valuation outputs we generate can be easily integrated with any in-house existing financial systems, presentation styles or platforms that may be currently operational. This ensures a faster uptake within the business, enabling resources to be re-directed towards implementing the outputs and leveraging new information.
Our philosophy at Black Swan is to create the right environment using inclusive dialogues and collaboration that enable us to generate outputs that make business decisions clear. Our goal is to provide an unparalleled level of satisfaction and quality for our clients.
The Rx Price Index has helped us with understanding the European pharmaceutical market landscape. We were able to build our business case around value-based pricing by integrating competitor’s price points, European launch order and LOE driven price events. Furthermore, we could use our pricing assumptions in our commercial forecasts as the data was validated, robust, could be sourced and all margins and mark-ups were transparent and checked against the individual markets’ assumptions.
An Associate Director Market Access
Rx – Customer Review
Comprehension of the ‘true’ burden of disease is a factor which is undermined by poor epi-data and having dealt with previous suppliers I had entered negotiations tentatively with Black Swan Analysis. However, it was apparent after several calls with the team and a demo on the Epiomic platform that this offering was something very different. The granularity obtained by accurate segmentation of the data, detailed subpopulations and the ability to select/reject countries included in the analyses are factors which buoyed my interest in the product. But it was the outstanding aftercare by the team in answering questions which I had about specific ‘classification criteria’ and ‘treatment populations’ which lead to the extension of my organisations ‘universal subscription’. Finally, such is the confidence that we have in Epiomic that the resource has spanned several product teams and regions to become our sole epidemiological data source.
Business Development Manager
Epiomic – Customer Review
The unmet need for a robust and accessible Oncology forecasting platform has been apparent for many years, with many pharmaceutical/biotech’s (including our own) opting to outsource for bespoke models in order to understand the cancer landscape. However, having received delivery of several custom models from BSA, we were excited to investigate the functionality of their in-house platform (Oncostrat), the wide range of solid and liquid tumours across many major markets in the database allowed ‘our company’ to input regimens which are about to launch, generate dynamic models of the ‘share steals’ to best target as well as allowing us to vary launch dates in order to maximise our margins (and take advantage of other regimens LOE). This has ultimately led us to renew our license the platform!
Market Access EMEA – Oncology
Oncostrat – Customer Review
We have been incredibly satisfied with the work which Black Swan have provided my colleagues and I for the past few years. With several therapeutics in development and launching imminently, robust dynamic forecast models are essential for an accurate insight, Black Swan are fully capable of building and maintaining easy to understand models with considerable functionality. In addition, knowledge that their team conduct themselves with great professionalism and transparency is a factor which we hold in high regard and is fundamental for our repeat custom.
A Director of Global Rheumatology
Consulting – Customer Review